▲ Peaking
Business
🔮 fades
Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
Merck CEO expects breakthrough cancer vaccine to become faster to make
Moderna
38 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Moderna
This hub groups 38 separate news trends connected to Moderna, spanning June 19, 2026 through October 15, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 337 article observations and 304 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Cancer Vaccines Are the N.I.H.’s Next ‘Big Bet’
NIH to launch a cancer vaccine initiative
◼ Archived
Business
🔮 fades ✓
Moderna stock jumps on planned national cancer vaccine effort
Moderna stock jumps on planned national cancer vaccine effort
◼ Archived
Business
🔮 fades ✓
Why the FDA should not approve an ineffective multicancer screening test
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✓
Exclusive | She was ready to die. Now she’s in remission
A woman's remarkable recovery from cancer raises hopes for new vaccines.
◼ Archived
Business
🔮 fades ✓
Moderna CEO’s Realistic Approach to Innovation
4 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Moderna Stock Jumps. Its mRNA Cancer Vaccine Is Getting Ready for Its Next Big Test.
7 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✓
Flu season is coming: What to know about new vaccine, when to get your shot and more
New mRNA flu vaccine approved for adults 50 and older.
◼ Archived
Business
🔮 fades ✓
Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?
Moderna and Merck's mRNA cancer vaccine win marks a new treatment era.
◼ Archived
Health
🔮 fades ✓
What to know about the new mRNA flu vaccine
Moderna’s mRNA flu shot receives FDA clearance, promising broader immunity as flu season looms.
◼ Archived
Business
🔮 fades ✓
Personalized mRNA cancer vaccines offer new hope. We explain
Personalized mRNA cancer vaccines spark a biotech gold rush, drawing investors and reshaping oncology treatment.
◼ Archived
Health
🔮 fades ✓
When should you get your flu shot? Here’s what the experts say
Delaying the flu shot could cost vulnerable adults hospitalization, while new mRNA options arrive as experts push for early protection.
◼ Archived
Business
🔮 holds ✗
GSK catches phase 3 fever after mRNA flu vaccine beats standard shots
GSK's mRNA flu vaccine is advancing to Phase 3 trials after outperforming standard shots in Phase 2.
◼ Archived
Business
🔮 fades ✓
There’s a big change for this year’s flu shot: When should you be vaccinated?
GSK's mRNA flu vaccine is advancing to late-stage trials, potentially reshaping annual vaccination strategies.
◼ Archived
Business
🔮 fades ✓
23 best-performing stocks of August, as the software industry continues its recovery
The S&P 500's August rally has investors wondering what's next for the software industry
◼ Archived
Business
F.D.A. Approves New Covid Vaccines, and They Should Be Available Soon
The FDA has approved new Covid vaccines, but the companies that make them are already talking about availability.
◼ Archived
Business
🔮 fades ✓
What to Know About New Covid Vaccines for Fall 2026
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
Meta, Nvidia, Intuit, Salesforce, Moderna, Abercrombie, Zoom, and More Stocks That Explain Today’s Market
4 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
There’s a new type of flu vaccine for older adults this year. Can you get it?
A new mRNA flu vaccine for older adults has been approved, but availability remains uncertain.
◼ Archived
Business
How a Big Bet on Cancer Vaccines Brought Moderna Back from the Brink
Moderna's cancer vaccine trials could transform treatment, but the math is still out.
◼ Archived
Business
🔮 fades ✓
Moderna, Merck breakthrough could usher in wave of cancer vaccines
A cancer vaccine breakthrough is stirring debate over profits and public health, as Moderna and Merck's stock prices surge.
◼ Archived
Business
🔮 fades ✓
Quant hedge funds suffer worst day in 2 years as Treasury boosts buyback and Moderna shares leap
Quant hedge funds suffered their worst day in two years on August 20, 2026.
◼ Archived
Business
Stocks making the biggest moves premarket: Walmart, Coinbase, Moderna, Alibaba & more
Stocks are moving in premarket trading, with several major companies seeing significant activity.
◼ Archived
Business
🔮 fades ✓
Why Is Moderna Stock Down Today?
Moderna's stock is down despite promising news about a cancer vaccine.
◼ Archived
Business
🔮 fades ✓
After Moderna stock surge of 177% on cancer drug breakthrough, here's what Wall Street thinks happens next
Moderna's stock surge on a cancer drug breakthrough has Wall Street abuzz with speculation about the future of cancer treatment.
◼ Archived
Business
Wall St recovers as yields ease; Moderna lifts healthcare stocks
Investors see broad gains across stocks, bonds, gold, and bitcoin as a new Treasury buyback plan shifts market sentiment.
◼ Archived
Business
🔮 fades ✓
Moderna Shares Double on Success of mRNA Cancer Vaccine
Moderna's shares have doubled since August 19th, 2026, as investors react to a breakthrough in cancer treatment.
◼ Archived
Business
🔮 fades ✓
Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma
Shares of Moderna have doubled after its cancer vaccine trial with Merck met key endpoints.
◼ Archived
Business
Moderna surges as Merck-partnered melanoma vaccine cuts recurrence in large trial
Moderna's stock surges as a melanoma vaccine developed with Merck shows promise in a large trial
◼ Archived
Business
🔮 fades ✓
Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
Moderna's stock surged 160% after the company and Merck announced success in a late-stage melanoma vaccine trial
◼ Archived
Health
‘Mismatched’ vaccine being rolled out against Ebola outbreak
Public health agencies are deploying an Ebola vaccine that does not perfectly match the circulating virus strain while preparing new clinical trials.
◼ Archived
Business
🔮 holds ✗
F.D.A. Approves Moderna’s mRNA Flu Vaccine
The FDA's approval of Moderna's mRNA flu vaccine marks a significant shift in seasonal flu prevention, particularly for older adults.
◼ Archived
Health
🔮 fades ✓
FDA approves 1st mRNA flu shot, from Moderna
The FDA has approved the first mRNA flu vaccine, marking a significant shift in flu shot technology.
◼ Archived
Health
🔮 fades ✓
Moderna begins Phase 1 clinical trial of Ebola vaccine against strain behind DRC outbreak
Moderna's Phase 1 Ebola vaccine trial begins as the outbreak in DR Congo continues to spread
◼ Archived
Health
🔮 fades ✓
DR Congo Ebola outbreak kills more than 1,700 as WHO accelerates trials
An Ebola outbreak in the Democratic Republic of Congo has surpassed 1,700 deaths as Moderna initiates clinical trials for a new vaccine candidate.
◼ Archived
Business
🔮 fades ✓
Stock Market Today: S&P 500, Nasdaq Slip; Greenspan Tributes Roll In
Moderna's stock surge and tech sector volatility drive market trends as investors react to geopolitical developments.
◼ Archived
Business
🔮 fades ✓
New First-of-Its-Kind Flu Vaccine Approved by FDA Expert Panel
An FDA advisory panel has unanimously endorsed Moderna's first-of-its-kind mRNA-based seasonal influenza vaccine, mRNA-1010.